上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Efaproxiral sodium (Synonyms: RSR13 sodium) 纯度: 99.89%
Efaproxiral sodium (RSR13 sodium) 是一种血红蛋白 (Hb) 合成变构调节剂, 降低血红蛋白氧 (O2) 的结合亲和力。
Efaproxiral sodium Chemical Structure
CAS No. : 170787-99-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥770 | In-stock | |
50 mg | ¥700 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
Efaproxiral sodium 相关产品
•相关化合物库:
- Covalent Screening Library Plus
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Immunology/Inflammation Compound Library
- Metabolism/Protease Compound Library
- NF-κB Signaling Compound Library
- Stem Cell Signaling Compound Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Covalent Screening Library
- Antioxidants Compound Library
- Oxygen Sensing Compound Library
- Ferroptosis Compound Library
- Anti-COVID-19 Compound Library
- Pyroptosis Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Mitochondria-Targeted Compound Library
- Rare Diseases Drug Library
生物活性 |
Efaproxiral sodium (RSR13 sodium) is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy. in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical Trial |
|
||||||||||||||||
分子量 |
363.38 |
||||||||||||||||
Formula |
C20H22NNaO4 |
||||||||||||||||
CAS 号 |
170787-99-2 |
||||||||||||||||
中文名称 |
乙丙昔罗钠 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 39 mg/mL (107.33 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务